Research in contextMany children and young people with rheumatic diseases are treated with steroids for long periods. This, despite the advent of biological therapies. Osteoporosis is one of the major complications of steroids. For adults there are currently numerous evidence -- based therapeutic strategies to prevent bone loss. No such evidence exists for children and young people.When the British Society for Paediatric Rheumatology (BSPAR) surveyed paediatric rheumatologists in the UK regarding their practice, in their children and young people treated with steroids, there was no consensus on which drugs to use for skeletal protection (personal communication).Calcium and vitamin D supplementation, or bisphosphonates in those at higher risk, form the basis of current preventative treatment strategies.Older studies suggested calcitriol, or the calcitriol precursor alfacalcidol, increased areal BMD in adults with steroid-induced osteoporosis.Two trials have studied the efficacy of bisphosphonates in children with rheumatic diseases; one open label study demonstrated an improvement in aBMD whilst an underpowered RCT showed no improvement. Two randomised trials, using bisphosphonates, have been registered but both were abandoned due to failure to recruit. This demonstrates the difficulty of undertaking such trials in children and young people who are often quite ill due to their disease and parents reluctance to engage in additional drug therapies. A recent metanalysis found that the largest published prospective treatment study included only 44 children. A 2007 Cochrane review concluded that there was insufficient evidence to recommend bisphosphonates as standard therapy for the treatment of secondary paediatric osteoporosis.This is therefore the first and only fully powered randomised controlled trial to investigate whether the bisphosphonate risedronate or alfacalcidol results in clinical meaningful reduction in bone loss in children and young people with rheumatic diseases treated with steroids.The primary aim of this study was to determine the efficacy of risedronate or alfacalcidol compared to placebo in increasing lumbar spine aBMD z-score in children with rheumatic diseases, with the secondary aim of assessing the effect of the interventions on fracture rate.The results of this trial will be of great value to paediatricians and clinicians treating children and young people with steroids providing the only evidence --base for the efficacy of a bisphosphonate in this situation.Alt-text: Unlabelled Box

1. Background {#s0010}
=============

Chronic rheumatic diseases of childhood affect between 1 and 3 per 1000 children in the UK [@bb0005], [@bb0010]. Bone loss is a well-recognized major complication with considerable morbidity [@bb0015]. Major contributory factors include: the underlying inflammatory process [@bb0020] altered nutrition [@bb0025], growth impairment [@bb0030], reduced physical activity [@bb0035] and treatment, particularly glucocorticoids [@bb0015], [@bb0040], [@bb0045]. Steroids are detrimental to bone stock, however, despite the introduction of biologic drugs, for many children steroids remain the only means by which their disease can be controlled. Tens of thousands of children world-wide currently receive steroids for chronic rheumatic conditions. Steroids reduce peak bone mass and fracture risk increases as steroid dose increases [@bb0015], [@bb0045], [@bb0050]. Many more children receive recurrent courses of steroids for other common diseases such as asthma, with an associated increased risk of fracturing [@bb0055], [@bb0060].

Children receiving steroids can, unlike adults, dramatically increase their BMD when their disease is brought under control [@bb0065]. There is thus a tension between effective disease control and the adverse effects of the steroid therapy.

The current guidelines for adults are that those treated with GCs should receive prophylactic treatment for the prevention of bone loss [@bb0070]. No such recommendations are in place for children.

When the British Society for Paediatric Rheumatology (BSPAR) surveyed paediatric rheumatologists in the UK regarding their practice, there was no consensus on which drugs to use for skeletal protection (personal communication).

Calcium and vitamin D supplementation, or bisphosphonates in those at higher risk, form the basis of current preventative treatment strategies.

Older studies suggested calcitriol, or the calcitriol precursor alfacalcidol, increased aBMD in adults with steroid-induced osteoporosis [@bb0075], [@bb0080].

Two trials have studied the efficacy of bisphosphonates in children with rheumatic diseases; one open label study demonstrated an improvement in aBMD whilst an underpowered RCT showed no improvement [@bb0085], [@bb0090]. A 2007 Cochrane review concluded that there was insufficient evidence to recommend bisphosphonates as standard therapy for the treatment of secondary paediatric osteoporosis [@bb0095]. A recent metanalysis found that the largest published prospective treatment study included only 44 children [@bb0100].

The primary aim of this study was to determine the efficacy of risedronate or alfacalcidol compared to placebo in increasing lumbar spine aBMD z-score in children with rheumatic diseases, with the secondary aim of assessing the effect of the interventions on fracture rate.

2. Methods {#s0015}
==========

This randomised double blind placebo controlled trial was conducted on behalf of the British Society of Paediatric and Adolescent Rheumatology (BSPAR); the study was approved by OREC Northern Ireland and registered with EuDRACT No: 2005-003129-23; ISRCTN66814619.

Patients were recruited from eleven sites throughout the UK. Trial duration was one year with three months post-trial follow-up. The trial ran from 22/Aug/2007 to 27/Feb/2013.

Children and adolescents with Juvenile Idiopathic Arthritis (JIA), Juvenile Systemic Lupus Erythematosus (JSLE), Juvenile Dermatomyositis (JDM) or vasculitis, between the ages of four and 18 years, commencing or established on steroid therapy, were eligible to participate. Protocol details are in Supplementary data.

Written informed consent was obtained from all parents/guardians and consent/assent obtained from all patients prior to starting the study.

Participants were stratified according to:⁎Tanner stage (0--2; 3--5)⁎Steroid dose (prednisolone equivalent) (Low ≤ 0.2 mg/kg/d) Vs medium-high (\> 0.2 mg/kg/d)

Subjects were randomised in an independent central randomisation facility (Clinical Research Support Centre NI) into three groups, according to stratification information included in the registration form, in a1:1 ratio to receive:

Group 1. Alfacalcidol/risedronate placebo.

Group 2. Alfacalcidol 15 ng/kg/day (max 1 μg).

Group 3. Risedronate 1 mg/kg/week for body weight \< 30kgs, or 35 mg/wk. for body weight \> 30 kgs.

The risedronate and risedronate placebo were identical as were the alfacalcidol and placebo.

All children received a supplement of 500 mg calcium and 400 IU vitamin D daily.

The research nurse faxed the registration information to the CRSC where they were randomised to receive a study number which the research nurse obtained by Fax. Simultaneously the trial pharmacist in each study centre received the same number to dispense the appropriated coded and blinded medication. The study pharmacists were not blinded to the treatment dispensed. They had no further involvement in the study. All persons involved in the study: staff, patients and parents were blinded to the study treatment.

2.1. Visit schedule {#s0020}
-------------------

Patients were assessed and randomised to treatment group at T0, and assessed every three months until study end. Throughout the trial, changes in anti-rheumatic therapy, including steroid dosage, were permitted according to locally-defined clinical need.

2.2. Clinical assessment {#s0025}
------------------------

The clinical parameters assessed at each visit were; height, weight skin fold thickness, Tanner score, JIA disease activity, (Childhood Health Assessment Questionnaire, British Isles Lupus Assessment Group Index, Childhood Myositis Assessment Score, fracture history. All menstruating females were tested for pregnancy.

2.3. Laboratory measurements {#s0030}
----------------------------

The following parameters were assessed in blood and urine at each visit. Samples were not obtained fasting as this was logistically difficult in children and would not be feasible in normal clinical practice.

Full blood picture (FBP); Erythrocyte sedimentation rate (ESR); C-reactive protein (CRP); Urea and Electrolytes (U&E); Bone profile; Urine Calcium/Creatinine ratio every 3 months. All centres used their hospital\'s standard ranges which were stored in the site files. Serum 25 hydroxyvitamin D (Immunodiagnostics, UK) and parathormone (Abbot Diagnostics, UK), bone alkaline phosphatase, Osteocalcin (measures of bone formation), and Crosslaps (measure of bone resorption) (Roche diagnostics, UK) were measured at T = 0 and at 3 months. The latter three were analysed centrally (Belfast Hospital Trust). Paediatric reference range was used for Crosslaps [@bb0105].

2.4. Radiological assessment {#s0035}
----------------------------

In the 11 participating centres, seven DXA scanners were Lunar Prodigy and four were Hologic. All participating DXA scanners were standardised using a paediatric spine phantom (MRC Mineral Metabolism Unit, Leeds, UK) [@bb0110]. The initial DXA scans were performed within two weeks of commencing the study and lumbar spine areal BMD (LSaBMD) and total body less head areal BMD (TBLHaBMD) were measured then and at visit 3 (6 months) and at visit 5 (12 months). LSaBMD and TBLHaBMD z-scores were either machine-derived or, for five patients under age five years, calculated by the Least Median Squares (LMS) method using UK reference data [@bb0115], [@bb0120].

Lateral radiographs of the spine for vertebral deformity were performed at baseline and month 12. All radiographs were read centrally and blindly by a consultant musculoskeletal radiologist (ME). Vertebral fractures were scored 0--3 using the Genant method [@bb0125] where **grade 0**: normal; **grade 1**: mild fracture, 20% to 25% loss of height; **grade 2**: moderate fracture, 25% to 40% loss of height; **grade 3**: severe fracture, greater than 40% loss of height.

2.5. Safety {#s0040}
-----------

Urinary calcium excretion was recorded as a safety measure. The numbers of patients experiencing adverse events (AEs) or serious adverse events (SAEs) and number of events are reported by treatment group. An adverse event is any untoward medical occurrence in a patient in the study. An adverse reaction (AR) is defined as any AE considered to have a possible, probable or definite relationship to the study drug.

2.6. Study details {#s0045}
------------------

Risedronate and its placebo were provided by Proctor and Gamble (subsequently Warner Chilcott UK). Alfacalcidol was obtained from Leo Laboratories (One Alpha, Leo laboratories) and the alfacalcidol placebo was made by Victoria Pharmaceuticals, Belfast Hospital Trust. Calcium and vitamin D supplements were supplied by Victoria Pharmaceuticals.

None of the pharmaceutical companies had any input into the trial design or data analysis.

2.7. Study oversight {#s0050}
--------------------

The study was designed by the authors and the trial data input and analysis undertaken by the Northern Ireland Clinical Trials Unit (NICTU). The progress of the trial was monitored by the Data Monitoring and Ethics Committee of Arthritis Research UK (now Versus Arthritis). Data analysis was conducted by three of the authors.

2.8. Sample size calculation {#s0055}
----------------------------

There was little existing evidence on what was regarded as a clinically meaningful effect size.

The initial required sample size was 270 children. To detect an improvement between the treatment groups of 6.25 and between the treatment groups and the control groups of 6.25, using a SD of 12.5, observed in our 1 year growth hormone study [@bb0030], 75 children were required in each of the three study arms; with 80% power to detect a significant difference at the 5% level of significance. We further expected a dropout rate of 15%, and that approximately 20% of this population would not receive steroids for one year. Thus to ensure that an adequate number of children would complete the study on steroids we required 90 children per treatment group; a total of 270.

Interim analysis showed that there was much better retention rate and fewer stopping steroids. There were two re-assessments of sample size calculation. One assessment after reducing percentage of patients without efficacy endpoint as 15% and another re-calculation was done with 10% dropouts. The effect size was kept the same. The sample size was set to 216, with 10% drop out rate.

2.9. Statistical analysis {#s0060}
-------------------------

The efficacy measure was the change in BMD at year 1 follow-up from baseline. The primary outcome measure was the change from baseline in LSaBMD z-score and the primary analysis was carried out using ANOVA, to test whether there is a statistically significant difference between the groups. The post-hoc bonferroni test was carried out to check which pair differ significantly. (Placebo vs. Alfacalcidol, Placebo vs. Risedronate, Alfacalcidol vs. Risedronate).

Analysis of covariance was performed on Lumbar spine BMD at year 1 adjusting for Lumbar spine BMD at baseline, age and gender. A post-hoc pairwise comparison was carried out using Bonferroni test.

Patients whose drug was prematurely withdrawn were encouraged to have a DXA scan at one year and their results included in the analysis.

Intention-to- treat (ITT) population includes all patients who were randomised and who received at least one dose of the planned study medication. Per protocol analysis includes all the patients who received all doses of the study drug as per protocol.

The primary efficacy analysis was based on the ITT population, but a per-protocol analysis was also performed. Final analysis was unadjusted for the interim analysis.

The Secondary Outcome was the rate of vertebral or other fractures during the trial period.

Count of observations, mean ± SD, median (p25 to p50), and frequency (percentage) were used to summarise the variables.

3. Results {#s0065}
==========

Two hundred and seventeen patients were recruited from 11 participating centres throughout the UK and randomised to placebo (n = 77), alfacalcidol (n = 71), or risedronate (n = 69). Screening and recruitment information are shown in the consort flow diagram [Fig. 1](#f0005){ref-type="fig"}.Fig. 1CONSORT flow diagram.Fig. 1

Baseline demographics are shown in [Table 1](#t0005){ref-type="table"}.Table 1Baseline characteristics (population: intention to treat (ITT).Table 1VariablesPlaceboAlfacalcidolRisedronateAll PatientsN777169217Age (years), mean (SD)12.1 (3.5)12.1 (3.7)12.0 (3.4)12.1 (3.5)GenderFemale, n (%)55 (71.4)48 (67.6)53 (76.8)156 (71.9)Male, n (%)22 (28.6)23 (32.4)16 (23.2)61 (28.1)Tanner score, median (IQR)2 (1 to 4)2 (1 to 4)2 (1 to 3)2 (1 to 4)Steroid dose, n (%)≤ 0.2 mg/kg37 (48.0)30 (42.2)32 (46.4)99 (45.6)\> 0.2 mg/kg40 (52.0)41 (57.8)37 (53.6)118 (54.4)Ethnic origin, n (%)Caucasian59 (76.6)54 (76.1)55 (79.7)168 (77.4)Black4 (5.2)4 (5.6)6 (8.7)14 (6.4)Oriental0 (0)1 (1.4)0 (0)1 (0.5)Asian11 (14.3)10 (14.1)6 (8.7)27 (12.4)Other3 (3.9)2 (2.8)2 (2.9)7 (3.2)Disease group, n (%)JIA21 (27.3)30 (42.2)20 (29.0)71 (32.7)JSLE31 (40.3)21 (29.6)24 (34.8)76 (35.0)JDM17 (22.1)13 (18.3)16 (23.2)46 (21.2)Vasculitis11 (14.3)12 (16.9)13 (18.8)36 (16.6)Approximate cumulative steroid dose mg, mean (SD) (n = 206)[a](#tf0005){ref-type="table-fn"}8403.7 (9206.9)9108.7 (7528.0)8090.4 (9390.1)8531.5 (8721.8)Relevant medical conditions[b](#tf0010){ref-type="table-fn"} (yes), n (%)42 (55.3)39 (54.9)43 (62.3)124 (57.4)On any medications at baseline75 (98.7)69 (97.2)68 (98.6)212 (98.2)DMARDS[c](#tf0015){ref-type="table-fn"}\
Methotrexate, Mycophenolate Mofetil, Azathioprine, Cyclophosphamide, Hdroxychloroquine, Cyclosporine71 (93.4)64 (90.1)62 (89.9)197 (91.2)Biologics: Etanercept; Infliximab; Anakinra; Tocilizumab8 (10.5)17 (23.9)7 (10.1)32 (14.8)Prior fracture history (yes), n (%)13 (17.1)9 (12.7)8 (11.6)30 (13.89)[^1][^2][^3]

Ethnicity, gender, age, disease subtype, Tanner stage and steroid dose were evenly distributed between the three groups. There was no significant difference in the fracture history between the groups.

Some 90% of participants in each group were concurrently treated with a DMARD and biologic use was 10.5%, 23.9% and 10.1% in the three groups respectively. Five patients in the placebo group started steroids de novo and two in the alfacalcidol group. All other patients were already taking steroids at the start of the study. The calculated cumulative steroid dose from the available patient records, prior to the commencement of the trial averaged 8--9 g in each group. Details of relevant medical conditions are available in Table 1 of Supplementary data.

Kaplan Meier survival curves demonstrate similar retention rates between the three groups [Fig. 2](#f0010){ref-type="fig"}, although a slightly earlier drop out was noted in the risedronate group, there was no statistical difference between them.Fig. 2Kaplan-Meier survival curves. Time to study drug withdrawal according to treatment group (population: ITT).Fig. 2

Eighty four percent, 86% and 81% of the placebo, alfacalcidol and risedronate groups respectively were still taking steroids at one year with mean daily intake of 5.88; 5.82 and 6.17 mg of prednisolone daily respectively. Clinical indicators of disease activity were similar at one year as were biochemical markers of disease activity [Table 2](#t0010){ref-type="table"}.Table 2Steroid doses anthropometric values and disease activity markers at baseline and one year (population: ITT).Table 2VariableVisitMean (SD)PlaceboAlfacalcidolRisedronateDaily Prednisolone[a](#tf0020){ref-type="table-fn"}\
Mean ± SDBaseline76\
12.20 [(]{.ul}8.83)70\
13.83 [(]{.ul}10.97)69\
16.91 [(]{.ul}22.69)One year65\
5.88 [(]{.ul}6.40)59\
5.82 (4.83)55\
6.17 [(]{.ul}5.44)Height cmsBaseline145.0 (18.6)145.3 (21.3)144.6 (19.9)One year149.0 (15.5)149.9 (20.2)148.7 (19.2)Weight KgBaseline46.14 (17.41)48.24 (20.79)48.05 (18.87One year49.82 (17.85)53.62 (23.08)51.56 (18.79)Hb g/dlBaseline12.8 (1.36)12.6 (1.31)12.5 (1.25)One year12.6 (1.53)12.5 (1.14)12.5 (1.12)ESR mm/hBaseline14.7 (17.1)16.2 (13.6)14.7 (16.7)One year11.0 (11.7)15.9 (17.8)16.0 (21.5)CRP mg/LBaseline5.2 (5.8)7.8 (11.4)7.8 (9.5)One year4.8 (5.2)6.2 (6.2)the5.7 (5.7)ALP IU/LBaseline187.0 (126.6)196.1 (133.2)179.1 (112.4)One year217.8 (158.5)233.4 (191.9)214.9 (155.8)[^4][^5]

3.1. Efficacy analysis {#s0070}
----------------------

The primary outcome was the change in LSaBMD z-score at one year from baseline which together with LSaBMD, TBLHaBMD, and TBLHaBMD z-score are summarised in [Table 3](#t0015){ref-type="table"}, with the efficacy analysis in [Table 4](#t0020){ref-type="table"}. For transparency the BMD values without and with the calculated results are shown. For all subsequent aBMD results in subsequent tables, the values shown are the calculated values.Table 3Areal BMD gm/cm^2^ and areal BMD z-scores over during the course of the study (population: ITT).Table 3N, mean (SD)PlaceboAlfacalcidolRisedronateLumbar Spine aBMD g/cm^2^Screening76, 0.76 (0.20)71, 0.79 (0.21)68, 0.78 (0.19)6 month68, 0.79 (0.18)63, 0.80 (0.22)59, 0.82 (0.19)One-year72, 0.80 (0.19)67, 0.83 (0.21)58, 0.85 (0.17)  Lumbar spine aBMD z scoreScreening76, − 1.15 (1.15)68, − 0.91 (1.04)66, − 1.04 (1.17)Screening-calculated[a](#tf0025){ref-type="table-fn"}76, − 1.15 (1.15)71, − 0.96 (1.04)68, − 0.99 (1.19)6 month68, − 1.17 (1.07)61, − 0.95 (1.12)57, − 0.84 (1.16)6 month-calculated[a](#tf0025){ref-type="table-fn"}68, − 1.17 (1.07)63, − 1.01 (1.15)59, − 0.79 (1.18)One-year72, − 1.13 (1.10)67, − 0.99 (1.07)58, − 0.74 (1.17)One-year-calculated[a](#tf0025){ref-type="table-fn"}72, − 1.13 (1.10)67, − 1.00 (1.07)58, − 0.75 (1.15)  Total body less head aBMD g/cm^2^Screening75, 0.91 (0.14)70, 0.93 (0.16)68, 0.91 (0.13)6 month68, 0.93 (0.13)62, 0.94 (0.17)58, 0.93 (0.13)One-year70, 0.92 (0.12)65, 0.97 (0.16)59, 0.96 (0.13)  Total body less head aBMD z scoreScreening75, − 0.57 (0.99)67, − 0.4 (1.09)66, − 0.63 (1.08)Screening-calculated[a](#tf0025){ref-type="table-fn"}75, − 0.57 (0.99)70, − 0.63 (1.64)68, − 0.65 (1.08)6 month68, − 0.62 (0.99)59, − 0.29 (1.19)56, − 0.50 (1.08)6 month-calculated[a](#tf0025){ref-type="table-fn"}68, − 0.62 (0.99)62, − 0.49 (1.55)58, − 0.52 (1.08)One-year70, − 0.70 (0.94)65, − 0.46 (1.28)59, − 0.46 (1.09)One-year-calculated[a](#tf0025){ref-type="table-fn"}70, − 0.70 (0.94)65, − 0.57 (1.47)59, − 0.44 (1.08)[^6][^7]Table 4Efficacy analysis: change in areal BMD and areal BMD z-scores from baseline to one year (population: ITT).Table 4Change from baseline to 1 yearMean (SD)p-ValueAlfacalcidol vs placeboRisedronate vs placeboRisedronate vs alfacalcidolPlaceboAlfacalcidolRisedronateMean difference\
(95% CI)p-ValueMean difference\
(95% CI)p-ValueMean difference\
(95% CI)p-ValuePrimary outcome measure: change in lumbar spine aBMD-Z scorePrimary analysis - ITT− 0.036 (0.435)− 0.088 (0.519)0.238 (0.551)0.0007− 0.052 (− 0.257, 0.153)1.00.274 (0.061, 0.487)0.0070.326 (0.109, 0.543)0.001Per protocol− 0.043 (0.431)− 0.036 (0.510)0.264 (0.540)0.00080.007 (− 0.204, 0.219)1.00.307 (0.092, 0.521)0.0020.300 (0.078, 0.522)0.004ANCOVA0.0004− 0.024 (− 0.219 to 0.171)1.00.286 (0.083 to 0.488)0.0020.311 (0.104 to 0.516)0.001  Change in lumbar spine aBMD g/cm^2^ITT0.034 (0.047)0.031 (0.052)0.069 (0.057)0.0001− 0.002 (− 0.023, 0.019)1.00.036 (0.014, 0.058)\< 0.0010.038 (0.015, 0.060)\< 0.001Per protocol0.034 (0.048)0.036 (0.051)0.072 (0.055)0.00010.002 (− 0.020, 0.024)1.00.038 (0.015, 0.060)\< 0.0010.036 (0.013, 0.059)0.001ANCOVA0.0001− 0.001 (− 0.022, 0.021)1.00.036 (0.014, 0.059)\< 0.0010.037 (0.015, 0.060)\< 0.001  Change in total body less head aBMD g/cm^2^ITT0.016 (0.032)0.029 (0.034)0.040 (0.030)0.00010.014 (0.001, 0.027)0.0350.025 (0.011, 0.038)\< 0.0010.011 (− 0.003, 0.025)0.1Per protocol0.016 (0.032)0.032 (0.034)0.041 (0.030)0.00010.015 (0.002, 0.029)0.0240.025 (0.011, 0.039)\< 0.0010.010 (− 0.005, 0.024)0.3  Change in total body less head aBMD-Z scoreITT− 0.129 (0.458)0.012 (0.505)0.169 (0.415)0.00160.141 (− 0.051, 0.333)0.20.298 (0.101, 0.495)0.0010.157 (− 0.043, 0.358)0.1Per protocol− 0.103 (0.448)0.067 (0.476)0.182 (0.415)0.00210.170 (− 0.024, 0.365)0.10.285 (0.090, 0.481)0.0020.115 (− 0.086, 0.317)0.5

During the year of treatment, LSaBMD z-score was unchanged in the placebo group; − 1.15 to − 1.13; decreased from − 0.96 to − 1.00 in the alfacalcidol group and increased from − 0.99 to − 0.75 in the risedronate group.

LSaBMD and TBLHaBMD increased in all groups, the largest increase being in the risedronate group, the least in the placebo group.

Forest plots for mean (95% CI) change in lumbar spine BMD Score according to treatment group and tanner score and treatment group and steroid dose can be seen in Figs. 1 and 2 in Supplementary data.

The primary analysis using ANOVA showed that there was a statistically significant difference between the groups (p = 0.0007). Highly significant differences were observed between the change in LSaBMD z-scores between the placebo and risedronate groups; 0.274, (95% CI 0.061, 0.487; p \< 0.001) and between the risedronate and the alfacalcidol groups; 0.326 (95% CI 0.109, 0.543; p \< 0.001) but not between the placebo and alfacalcidol groups; − 0.052 (− 0.257, 0.153). The ANCOVA on LSaBMD z-score at one year, after adjusting for baseline covariates, showed that there is statistically significant between group difference (p = 0.0004) [Table 4](#t0020){ref-type="table"} shows the mean (95% CI) for the pairwise comparisons post ANCOVA. [Fig. 3](#f0015){ref-type="fig"}.Fig. 3a) Lumbar spine BMD, b) lumbar spine BMD Z-score, c) total body less head areal BMD and d) total body less head areal BMD z-scores by treatment group during the course of the study (population: ITT).Fig. 3

3.2. Fracture data {#s0075}
------------------

Non-vertebral fracture rates in the placebo, alfacalcidol and risedronate groups were 5.3 (n = 4), 2.8 (n = 2) and 7.2 (n = 5) respectively. There was no statistically significant difference in the fracture rate between the treatment groups (*Fisher\'s exact* p = 0.51).

One hundred and eighty-seven patients with pre and post treatment lateral spinal X-rays were scored, using the Genant scoring system. Fifty four patients in the Placebo arm had baseline Genant score of 0 which remained unchanged for all at one year. In the alfacalcidol group, in all of the 52 patients with baseline and one year radiographs the Genant score remained unchanged (50 scored 0, 1 scored 2, 1 scored 3). In the risedronate group, all the 53 patients had a Genant score of 0 at baseline; at one year 50 remained unchanged, 2 had a Genant score of 1 and 1 had a Genant score of 3.

3.3. Biochemical and haematological parameters {#s0080}
----------------------------------------------

There were no statistically significant differences in the biochemical profiles between the three treatment groups at baseline and at 3 months and one year. Twenty-five hydroxy Vitamin D levels were similar in all three groups at baseline and increased in all three groups at 3 months. Alkaline phosphatase increased in all three groups over one year. PTH (ng/l) fell in both the placebo and alfacalcidol groups during the first 3 months from 39.8 (19.9) to 32.6 (20.1) and 34.8 (19.9) to 28.2(17.6) respectively, whilst in the risedronate group it rose from 41 (24.2) to 45.4 (31.9). No change was observed in either calcium or phosphate and disease activity as measured by CRP remained similar between the three groups throughout the year of the study (see [Table 5](#t0025){ref-type="table"}).Table 5Mean (SD) of biochemical parameters by treatment arm (population: ITT).Table 5VariableVisitPlaceboAlfacalcidolRisedronateCalcium mmol/lBaseline2.4 (0.1)2.4 (0.1)2.4 (0.1)One year2.4 (0.1)2.4 (0.1)2.4 (0.1)Phosphate mmol/lBaseline1.4 (0.2)1.3 (0.3)1.3 (0.2)One year1.4 (0.2)1.3 (0.3)1.3 (0.2)25 hydroxy\
Vitamin D nmol/lBaseline49.2 (28.5)50.2 (26.6)44.8 (26.7)3 month[a](#tf0030){ref-type="table-fn"}59.9 (24.8)67.1 (41.3)63.5 (32.8)PTH ng/lBaseline39.8 (19.9)34.8 (19.9)41.0 (24.2)3 month32.6 (20.1)28.7 (17.6)45.4 (31.9)ALP IUBaseline187.0 (126.6)196.1 (133.2)179.1 (112.4)One year217.8 (158.5)233.4 (191.9)214.9 (155.8)CRP mg/lBaseline5.2 (5.8)7.8 (11.4)7.8 (9.5)One year4.8 (5.2)6.2 (6.2)5.7 (5.7)[^8]

3.4. Bone markers {#s0085}
-----------------

Changes in bone alkaline phosphatase, osteocalcin and crosslaps are shown in Supplementary data Table 2. None of the bone markers predicted the change in BMD at one year.

3.5. Safety {#s0090}
-----------

Among 217 patients who were randomised to the trial, 215 patients received at least one dose of study drug and 180 patients experienced at least one adverse event. There was no statistically significant difference between the number of patients experiencing AEs and SAEs between the groups. Higher SAEs were observed in the risedronate group compared to placebo group but only one of these was an adverse reaction i.e. possibly related to the treatment ([Table 6](#t0030){ref-type="table"}). Further details on the types of SAEs are available in Supplementary data Table 3.Table 6Adverse events and serious adverse event summary (safety population).Table 6Placebo n = 77Alfacalcidol n = 71Risedronate n = 69Number of patientsExperiencing an AE n625959 Proportion (95% CI)0.81 (0.70 to 0.89)0.83 (0.72 to 0.91)0.86 (0.75 to 0.93)Experiencing an SAE n181421 Proportion (95% CI)0.23 (0.14 to 0.34)0.20 (0.11 to 0.31)0.30 (0.20 to 0.43)  Number of eventsNumber of AEs308260292Proportion (95% CI)0.36 (0.33 to 0.39)0.30 (0.27 to 0.33)0.34 (0.31 to 0.37)Number of ARs[a](#tf0035){ref-type="table-fn"}171115Proportion (95% CI)0.40 (0.25 to 0.56)0.26 (0.14 to 0.41)0.35 (0.21 to 0.51)Number of SAEs212231Proportion (95% CI)0.28 (0.19 to 0.40)0.30 (0.20 to 0.41)0.42 (0.31 to 0.54)Number SARs021Proportion (95% CI)0.33 (0.01 to 0.91)0.67 (0.09 to 0.99)0 (0.0 to 0.71)[^9]

4. Discussion {#s0095}
=============

We have demonstrated that the bisphosphonate risedronate significantly increased LSaBMD z-score in children and young people (CYP) receiving steroids for the treatment of their rheumatological disease, compared to those receiving alfacalcidol or vitamin D and calcium alone. The improvement in LSaBMD z-score for our CYP treated with risedronate was substantially greater than the increases in BMD typically observed in adult studies of glucocorticoid-induced osteoporosis [@bb0130]. Our trial was not powered to study the impact of risedronate on fracture rates in CYP; such a trial might require several thousand participants. We observed a 28% increase in BMD z-score in children treated with risedronate compared to a 2% increase and a 10% decrease in CYP treated with placebo or alfacalcidol. Whilst one cannot draw a direct comparison between improvements in adult and CYP BMD T and Z scores, very modest improvements of 6% in BMD in women treated with a bisphosphonate resulted in an almost halving of fractures [@bb0135] Furthermore in a study of children with osteogenesis imperfecta treated with bisphosphonates a difference in z-score of 0.387 between the treated and placebo groups was associated with a 47% decrease in fracture rate [@bb0140].

This is the first fully powered blinded randomised controlled trial into the prevention and treatment of osteopenia in this population. Two previous RCTs were terminated due to failure to recruit demonstrating the difficulty of undertaking such trials in CYP [@bb0145], [@bb0150].

We suggest that in association with our observed increase in BMD, fracture risk should also be reduced, even though the observed increase in LSaBMD z-score was less than the hoped-for 0.5.

Many paediatric rheumatologists use alfacalcidol rather than bisphosphonates, as they consider it safer; there was evidence that this prodrug could also improve BMD in adult patients treated with steroids [@bb0075], [@bb0080]. Our study demonstrates that alfacalcidol has no impact on LSaBMD z-score in children with inflammatory conditions receiving glucocorticoids. Alfacalcidol did result in a significant improvement in TBLHaBMD, but not TBLHaBMD z-score, that is, not after accounting for changes due to age and sex. Alfacalcidol is not without risk; as it bypasses the normal renal regulation, excessive alfacalcidol administration can result in serious hypercalcaemia and organ damage [@bb0155].

The acquisition of adequate peak bone mass is not only important for the young person in reducing fracture risk but also has significant implications for the development of osteoporosis in later life, if peak bone mass is suboptimal.

We had hoped that early changes in bone markers might identify those patients who were or were not responding to treatment, allowing timely changes to be made to patient\'s management. However in our population, bone markers were not able to predict which patients responded best to treatment. Alkaline phosphatase levels increased in all three treatment groups over time as would be expected in growing CYP. The increase in PTH levels in the risedronate group at 3 months is probably due to the effective inhibition of bone resorption which induces a reduction in serum calcium leading to increased parathyroid hormone (PTH) levels.

All therapeutic interventions were well tolerated and the side effect profiles were similar between all three groups. Whilst SAEs in the risedronate group were 7% higher than in the control group there was no difference in the SARs where the reactions were considered to be related to the treatment. SAEs in the risedronate group and were primarily related to disease flares. This study is not large enough to evaluate whether bisphosphonates might induce disease flares. I should be noted that the participants in this trial all had moderate to severe disease, requiring steroids, thus disease flares would be expected.

Avascular necrosis of the mandible has been reported in adults treated with bisphosphonates [@bb0160]. We had no such cases and have not identified any in the literature in children.

The long-term effects of bisphosphonates in growing children have as yet not been fully evaluated, although longitudinal cohort studies of children with OI (most often exposed to these drugs) are generally reassuring \[33\].

5. Conclusion {#s0100}
=============

We have demonstrated that the bisphosphonate risedronate results in statistically and, we believe, clinically meaningful increases in bone mass in both the whole body and the lumbar spine, a site at particular risk for fracture in children with low bone mass in association with inflammatory conditions. The drug was well tolerated with no significant increase in side effects over the comparators. We would advise consideration of risedronate in children and young people with inflammatory conditions receiving steroids, especially those considered at higher risk for fracture.

Appendix A. Supplementary data {#s0115}
==============================

Supplementary materialImage 1
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[^1]: One patient in placebo had a cumulative steroid dose of 238,325 mg and one patient in the alfacalcidol arm had a cumulative dose of 487,400 mg. These values were excluded in the mean (SD) calculation.

[^2]: Details of relevant medical conditions are available in [Table 1](#t0005){ref-type="table"}.

[^3]: Disease modifying anti rheumatic drugs.

[^4]: One in placebo, 4 in alfacalcidol and 4 in risedronate groups. For these, the daily prednisolone equivalent was calculated.

[^5]: Two patients were treated with deflazacort, and one hydrocortisone. Nine patients received methylprednisolone pulses.

[^6]: Least Median Squares (LMS) method [@bb0110].

[^7]: Includes z-scores for five patients (all visits) who were below five years of age that were calculated using.

[^8]: Some parameters were only measured at baseline and 3 months.

[^9]: An AE with a definite/probable/possible relationship to the study drug is considered as an AR.
